These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
275 related articles for article (PubMed ID: 26821497)
1. [RESISTANCE OF HCV TO NEW DIRECT ACTING ANTIVIRALS]. Gozlan Y; Mendelson E; Ben-Ari Z; Mor O Harefuah; 2015 Nov; 154(11):684-7, 743. PubMed ID: 26821497 [TBL] [Abstract][Full Text] [Related]
2. Current race in the development of DAAs (direct-acting antivirals) against HCV. De Clercq E Biochem Pharmacol; 2014 Jun; 89(4):441-52. PubMed ID: 24735613 [TBL] [Abstract][Full Text] [Related]
3. Identification of drug resistance and immune-driven variations in hepatitis C virus (HCV) NS3/4A, NS5A and NS5B regions reveals a new approach toward personalized medicine. Ikram A; Obaid A; Awan FM; Hanif R; Naz A; Paracha RZ; Ali A; Janjua HA Antiviral Res; 2017 Jan; 137():112-124. PubMed ID: 27984060 [TBL] [Abstract][Full Text] [Related]
4. Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naïve Patients Infected with Genotype 1b Hepatitis C Virus. Wang Y; Rao HY; Xie XW; Wei L Chin Med J (Engl); 2015 Oct; 128(19):2625-31. PubMed ID: 26415801 [TBL] [Abstract][Full Text] [Related]
5. Use of whole genome sequencing in the Dutch Acute HCV in HIV study: focus on transmitted antiviral resistance. Christiansen MT; Hullegie SJ; Schutten M; Einer-Jensen K; Tutill HJ; Breuer J; Rijnders BJA Clin Microbiol Infect; 2017 Feb; 23(2):123.e1-123.e4. PubMed ID: 27693529 [TBL] [Abstract][Full Text] [Related]
6. Directly acting antivirals against hepatitis C virus: mechanisms of action and impact of resistant associated variants. Premoli C; Aghemo A Minerva Gastroenterol Dietol; 2016 Mar; 62(1):76-87. PubMed ID: 26448306 [TBL] [Abstract][Full Text] [Related]
7. Geno2pheno[HCV] - A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral Agents. Kalaghatgi P; Sikorski AM; Knops E; Rupp D; Sierra S; Heger E; Neumann-Fraune M; Beggel B; Walker A; Timm J; Walter H; Obermeier M; Kaiser R; Bartenschlager R; Lengauer T PLoS One; 2016; 11(5):e0155869. PubMed ID: 27196673 [TBL] [Abstract][Full Text] [Related]
8. Naturally occurring NS3 resistance-associated variants in hepatitis C virus genotype 1: Their relevance for developing countries. Echeverría N; Betancour G; Gámbaro F; Hernández N; López P; Chiodi D; Sánchez A; Boschi S; Fajardo A; Sóñora M; Moratorio G; Cristina J; Moreno P Virus Res; 2016 Sep; 223():140-6. PubMed ID: 27449600 [TBL] [Abstract][Full Text] [Related]
11. A Prospective Italian Study on Baseline NS3 and NS5A Resistance to Direct-Acting Antivirals in a Real-World Setting of HIV-1/HCV Coinfected Patients and Association with Treatment Outcome. Bagaglio S; Hasson H; Peano L; Vercesi R; Messina E; Galli A; Foppa CU; Morsica G Viruses; 2020 Feb; 12(3):. PubMed ID: 32121164 [TBL] [Abstract][Full Text] [Related]
12. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge. De Monte A; Courjon J; Anty R; Cua E; Naqvi A; Mondain V; Cottalorda J; Ollier L; Giordanengo V J Clin Virol; 2016 May; 78():27-30. PubMed ID: 26967675 [TBL] [Abstract][Full Text] [Related]
13. Hepatitis C virus resistance to protease inhibitors. Halfon P; Locarnini S J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949 [TBL] [Abstract][Full Text] [Related]
14. Pipeline for specific subtype amplification and drug resistance detection in hepatitis C virus. Soria ME; Gregori J; Chen Q; García-Cehic D; Llorens M; de Ávila AI; Beach NM; Domingo E; Rodríguez-Frías F; Buti M; Esteban R; Esteban JI; Quer J; Perales C BMC Infect Dis; 2018 Sep; 18(1):446. PubMed ID: 30176817 [TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus resistance to the new direct-acting antivirals. Esposito I; Trinks J; Soriano V Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1197-209. PubMed ID: 27384079 [TBL] [Abstract][Full Text] [Related]
16. Genetic background for development of resistance mutations within the HCV NS3 protease-helicase in direct acting antiviral naive patients. Grammatikos G; Jabara CB; Ahmad MQ; Herrmann E; Zeuzem S; Welsch C Antivir Ther; 2014; 19(5):455-61. PubMed ID: 24457994 [TBL] [Abstract][Full Text] [Related]
17. Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b. Kanda T; Nirei K; Matsumoto N; Higuchi T; Nakamura H; Yamagami H; Matsuoka S; Moriyama M World J Gastroenterol; 2017 Dec; 23(46):8120-8127. PubMed ID: 29290649 [TBL] [Abstract][Full Text] [Related]
18. Performance assessment of a fully automated deep sequencing platform for HCV resistance testing. Rodriguez C; Mercier-Darty M; Soulier A; Poiteau L; Wlassow M; Fourati S; Hézode C; Pawlotsky JM; Chevaliez S Antivir Ther; 2019; 24(6):417-423. PubMed ID: 31112134 [TBL] [Abstract][Full Text] [Related]
19. Genetic Barrier to Direct Acting Antivirals in HCV Sequences Deposited in the European Databank. Kliemann DA; Tovo CV; Gorini da Veiga AB; Machado AL; West J PLoS One; 2016; 11(8):e0159924. PubMed ID: 27504952 [TBL] [Abstract][Full Text] [Related]
20. Update on hepatitis C virus resistance to direct-acting antiviral agents. Poveda E; Wyles DL; Mena A; Pedreira JD; Castro-Iglesias A; Cachay E Antiviral Res; 2014 Aug; 108():181-91. PubMed ID: 24911972 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]